Skip to Content

Siliq Approval History

FDA Approved: Yes (First approved February 15, 2017)
Brand name: Siliq
Generic name: brodalumab
Dosage form: Injection
Company: Bausch Health Companies Inc.
Treatment for: Plaque Psoriasis

Siliq (brodalumab) is a human anti-interleukin-17-receptor monoclonal antibody for the treatment of plaque psoriasis.

Development History and FDA Approval Process for Siliq

DateArticle
Feb 15, 2017Approval FDA Approves Siliq (brodalumab) for Plaque Psoriasis
Jul 19, 2016FDA Advisory Committee Recommends Approval Of Brodalumab For Treatment Of Moderate-To-Severe Plaque Psoriasis
Jan 26, 2016Valeant Announces FDA Acceptance of BLA Submission for Brodalumab in Moderate-to-Severe Plaque Psoriasis
Sep  1, 2015AstraZeneca and Valeant Pharmaceuticals to Partner on Brodalumab
May 22, 2015Amgen to Terminate Participation in Co-Development and Commercialization of Brodalumab
Nov 25, 2014Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab
Nov 11, 2014Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide